We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI's Strategic Push to Expand Beyond Oncology
Read MoreHide Full Article
Key Takeaways
Tempus AI is expanding its algorithms beyond oncology into pathology, radiology, cardiology and neuropsych.
TEM secured two FDA 510(k) clearances for its cardiac imaging update and ECG-Low EF software.
Tempus AI strengthened its platform by acquiring Arterys in 2022 and Paige's digital pathology dataset.
Tempus AI (TEM - Free Report) is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, radiology, cardiology and neuropsych.
In line with this, it began a collaboration with Northwestern University’s Abrams Center to harness AI for rapid discovery and innovation in Alzheimer’s disease research. The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyze and restructure the center’s repository of genomic data.
Also, in the past few months, the company secured two new FDA 510(k) clearances. First, it received approval for the updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis. TEM also received approval for its ECG–Low EF software, which leverages AI to identify patients who may have redAuced left ventricular ejection fraction (LVEF).
Additionally, its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data ranging from lung CT scans and chest X-rays to cardiac MRIs into Tempus’ platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus’ efforts.
Peer Update
GE HealthCare (GEHC - Free Report) recently launched its Voluson Performance series, the latest addition to its leading women’s health ultrasound portfolio. The company also entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders. GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems for seamless workflow.
Earlier this year, NANO-X IMAGING LTD (NNOX - Free Report) received CE mark certification to market the multi-source Nanox.ARC system, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system, intended to generate tomographic images of human anatomy from a single tomographic sweep performed in recumbent positions of adult patients.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have rallied 74% against the industry’s 1.5% decline. The S&P 500 composite has improved 14.5% in the same time.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.76X compared with the industry average of 5.77X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has remained unchanged.
Image: Bigstock
Tempus AI's Strategic Push to Expand Beyond Oncology
Key Takeaways
Tempus AI (TEM - Free Report) is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data. These algorithms span beyond oncology, including digital pathology, radiology, cardiology and neuropsych.
In line with this, it began a collaboration with Northwestern University’s Abrams Center to harness AI for rapid discovery and innovation in Alzheimer’s disease research. The collaboration leverages Tempus’ AI-powered data analytics platform, Lens, to analyze and restructure the center’s repository of genomic data.
Also, in the past few months, the company secured two new FDA 510(k) clearances. First, it received approval for the updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis. TEM also received approval for its ECG–Low EF software, which leverages AI to identify patients who may have redAuced left ventricular ejection fraction (LVEF).
Additionally, its strategic acquisitions have further strengthened its footprint in these fields. In 2022, Tempus acquired Arterys, incorporating its AI-powered tools for analyzing imaging data ranging from lung CT scans and chest X-rays to cardiac MRIs into Tempus’ platform. Most recently, Tempus acquired Paige, an AI company specializing in digital pathology, bringing a proprietary dataset of almost 7 million clinically annotated, de-identified pathology slides to accelerate Tempus’ efforts.
Peer Update
GE HealthCare (GEHC - Free Report) recently launched its Voluson Performance series, the latest addition to its leading women’s health ultrasound portfolio. The company also entered into an agreement to acquire icometrix, a company focused on providing AI-powered brain imaging analysis for neurological disorders. GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems for seamless workflow.
Earlier this year, NANO-X IMAGING LTD (NNOX - Free Report) received CE mark certification to market the multi-source Nanox.ARC system, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system, intended to generate tomographic images of human anatomy from a single tomographic sweep performed in recumbent positions of adult patients.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have rallied 74% against the industry’s 1.5% decline. The S&P 500 composite has improved 14.5% in the same time.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.76X compared with the industry average of 5.77X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has remained unchanged.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.